Best ePRO and eCOA Software in 2026: 8 Vendors Compared

Which ePRO or eCOA platform should you choose in 2026?

No single ePRO or eCOA platform fits every study. The choice starts with one question: should your outcome data sit on the same patient record as your clinical data, or in a specialist system that sends it to your EDC? Datacapt answers the first case, with ePRO, EDC, eConsent and randomization on one database and questionnaires built by configuration instead of development.

The eight vendors below are grouped by where your outcome data lands, from platforms that run ePRO next to their own EDC to the endpoint specialists that anchor global pivotal trials. Every entry states what the platform does well and where it stops, Datacapt included. ePRO, the questionnaires patients complete themselves, is one type of eCOA, which also covers clinician-reported, observer-reported and performance outcomes. Our article on how ePRO and eCOA differ sets out the four types.

Every claim about a vendor in this comparison comes from that vendor's public product pages, checked on 12 November 2026. Datacapt publishes this comparison and includes its own platform, with its limitations stated alongside the others.

How does the ePRO and eCOA market split in 2026?

The market splits three ways. Unified eClinical platforms run ePRO on the same database as their EDC. Endpoint specialists sell eCOA with the scientific and logistics services that global pivotal trials need. A third model runs eCOA as a managed service connected to whichever EDC the sponsor already uses.

The European Medicines Agency (EMA) gave the category its own annex in 2023. Annex 5 of its guideline on computerised systems and electronic data in clinical trials covers eCOA and bring-your-own-device (BYOD) collection, and asks sponsors to describe in the protocol how outcome data reaches the investigator. The way a platform moves data between the patient, the site and the database is therefore part of what an inspector reads.

The table below sorts the eight vendors by the model they sell.

💡 ePRO on the same record as the EDC. Outcome data and clinical data in one database: Datacapt, Medidata, Medrio, Viedoc.

Datacapt

Datacapt runs patient questionnaires on the same database as its EDC, eConsent and randomization. A patient's questionnaires, scores and reminders sit in the record the site completes, so the data manager reviews one dataset instead of reconciling two.

Strengths

• Questionnaires built in a visual builder, with scales, dates, scores and conditional logic, and published without a developer
• A library of validated instruments with their scoring in place, where each instrument records its licence and copyright holder and the attribution stays on the form the patient reads
• BYOD on any smartphone, tablet or computer without an app download, and provisioned devices for patients who need one
• Questionnaires triggered by study events, such as a completed visit or a status change, with SMS, email and QR code invitations
• Reminders scheduled before and after the target date, which stop as soon as the patient answers
• Deployed in more than 85 languages, so international sites work from one questionnaire
• An open API and webhooks for teams that run an external EDC or CTMS

Limitations

• No rater training, scale licensing service or device logistics published: the sponsor secures the licences of copyrighted instruments and ships any provisioned devices
• No wearable or sensor integration published on the ePRO pages
• Smaller footprint than the endpoint specialists on global pivotal programs with clinician-rated endpoints

Published results

• CHRU Strasbourg sent 24 questionnaires per patient at set time points over several weeks; 85% of questionnaires were completed by patients on the platform, and teams were autonomous after one to two hours of training.
• Epilepsia Waves configured, tested and deployed its survey in four days with no prior technical experience, sent it to 250 patients, and reached a 92% completion rate in the first phase.
• CIDP runs eCRF, ePRO and eConsent in a single solution and offers a hybrid mode of collection for volunteers who are less comfortable with digital tools.

✅ Best for sponsors, CROs and academic teams that want patient questionnaires on the same record as their eCRF data, from Phase I to Phase IV.

Medidata eCOA

Medidata sells eCOA inside its patient experience range. Assessment data flows into Rave EDC, and the same patient application can also carry consent and payments.

Strengths

• One patient experience for eCOA, consent, payments and other study interactions
• Assessment data flows into Rave without a separate system to reconcile
• Provisioned devices and BYOD on iOS or Android, through the web or a mobile app
• Medidata Designer, a drag-and-drop builder with screen templates and visual workflow tools
• A partnership with Cogstate for rater training and data quality oversight in CNS trials

Limitations

• Medidata publishes an average eCOA study start of eight weeks
• The single-record benefit depends on running Rave as the EDC; a study on another EDC goes back to an integration between two systems

✅ Best for sponsors already running Rave, and CNS trials that need rater training tied to the eCOA.

Medrio ePRO

Medrio builds its ePRO on the same clinical data platform as its EDC. Outcome assessments flow into the study database and sit next to the data the site enters.

Strengths

• Full integration with Medrio EDC and its data management workflows
• Patient-reported, clinician-reported and observer-reported assessments
• Licensed instruments or ad hoc questionnaires
• BYOD with automated notifications, reminders and time-based schedules
• Medrio states that a study goes from contract to data capture in four weeks

Limitations

• The ePRO page describes BYOD and does not mention provisioned devices: ask how the study covers participants without a device of their own
• No language count published on the ePRO page

✅ Best for early-phase and mid-size studies that already run on Medrio EDC.

Viedoc Me

Viedoc Me is the patient-facing ePRO of the Viedoc platform. It runs as a web application on the participant's own device and feeds the Viedoc EDC.

Strengths

• Full integration with Viedoc EDC, with entries available to data managers as soon as they are saved
• No data stored on the participant's device
• Web-based BYOD on the participant's own device
• More than 50 languages
• Reminders by email or SMS

Limitations

• The Viedoc Me page describes BYOD and does not mention provisioned devices
• The page covers patient-reported data and does not mention clinician-reported or observer-reported outcomes

✅ Best for studies on Viedoc EDC that collect patient diaries and questionnaires.

💡 Endpoint specialists. Global pivotal trials with complex endpoints: Clario, Signant Health, YPrime.

Clario

Clario sells eCOA alongside its cardiac, respiratory, imaging and wearable endpoint solutions. Its devices capture ECG, spirometry, blood glucose and activity data and connect to the eCOA device.

Strengths

• Pre-built, validated assessment libraries, and an eCOA Rapid Start catalog of pre-validated, configured assessments
• BYOD, web or provisioned devices
• Studies in more than 120 countries and more than 100 languages
• Rater, participant and caregiver training
• A self-reported eC-SSRS for monitoring suicidal ideation and behavior
• An early-phase oncology offer that Clario states deploys in as little as two weeks

Limitations

• The eCOA page lists no EDC, so outcome data reaches the study database through an integration with another vendor's system
• The range is built for endpoint-heavy programs, which is more scope than a study with a single patient diary needs

✅ Best for global pivotal trials with cardiac, respiratory or CNS endpoints.

Signant Health

Signant Health pairs eCOA software with scientific, licensing and logistics services. Its in-house scientific and clinical experts implement the instruments.

Strengths

• An instrument library of more than 50 instruments, many in pre-approved versions that skip the author review step
• Electronic clinician ratings, with rater training and qualification
• Scale licensing and management handled by the vendor
• Language management and linguistic validation across the study
• Device provisioning, logistics and a patient helpdesk in the local language
• Provisioned devices, web or BYOD
• eCOA as an add-on module of Signant's own EDC on the SmartSignals Unified Platform, built in the same designer and stored in a single database

Limitations

• The single database applies when the study runs on Signant's EDC; a study on another EDC goes back to an integration between two systems
• A service-heavy model sized for multinational programs, which is more than a short single-country study needs

✅ Best for multinational pivotal trials that need clinician ratings, scale licensing and device logistics from one partner.

YPrime

YPrime sells eCOA, IRT and eConsent as integrated products. Its eCOA covers ePRO, eClinRO, eObsRO and ePerfO in one place.

Strengths

• The four types of outcome assessment in one platform
• Integration with YPrime IRT and eConsent; in a published case study, randomization runs from a participant device that works offline
• BYOD, provisioned devices, or both in the same study, by region and population
• More than 250 languages across more than 100 countries, with localization drafted by AI
• Integrations with wearables, glucometers and sensors feeding the same record

Limitations

• EDC is a separate system: YPrime plans the integration requirements around each study's systems
• Built for global execution, which is more than a small single-site study needs

✅ Best for global trials that combine eCOA with randomization (IRT) and eConsent.

💡 Managed eCOA service. eCOA built and run by the vendor, on its own EDC or connected to another: Castor.

Castor eCOA

Castor sells eCOA as an expert-backed service. Its team builds and manages the study. Outcome data shares one database with Castor EDC, or flows to whichever EDC the sponsor runs.

Strengths

• Patient, observer and clinician outcome data, collected from patients' own devices first
• Builds run by Castor's Professional Services, with the sponsor's team reviewing and approving
• ePRO, observer-reported and clinician-reported outcomes on one database and audit trail with Castor EDC
• Integration with any major EDC through webhooks and REST APIs
• Translations, licensing and device logistics managed by Castor
• A library of validated instruments in several languages, on web ePRO and a patient app

Limitations

• The vendor builds the study, so a team that wants to edit its own questionnaires should check what stays in its hands
• The single database applies when the study runs on Castor EDC; a study on another EDC goes back to an integration between two systems

✅ Best for sponsors that want eCOA delivered as a service, on Castor EDC or on the EDC they already run.

[[cta]]

Which ePRO or eCOA platform fits your study?

Start from your study rather than from the vendor list. The table matches the most common operational priorities with the vendors that answer them on their own product pages.

How do you evaluate an ePRO or eCOA vendor?

Five questions separate vendors faster than a feature grid.

1. Ask where the outcome data lands. On the same record as the eCRF, or in a second system that sends it to your EDC. The second option works, and it gives your data manager an integration to validate and a reconciliation to run at every data cut.
2. Ask how the study covers participants without a smartphone. The EMA guideline of 2023 states that trial participants should not be excluded from a trial if they cannot or will not use their own device, and asks for alternatives such as devices provided by the sponsor. A vendor that sells BYOD alone leaves that gap to you.
3. Ask who secures the instrument licences. Validated instruments used as endpoints often belong to an author or a copyright holder, who sets the terms of use and may review the electronic version. Find out whether the vendor handles that step, holds pre-approved versions, or leaves it with your team.
4. Ask what happens when a questionnaire changes mid-study. Check that answers already collected stay readable and analyzable against the version the patient saw.
5. Ask for a build of one of your own instruments. A stock demo shows a diary someone else designed. Your own schedule, windows and reminders show what the configuration model absorbs.

For the full method on collecting patient-reported data, read our guide on how to collect patient-reported outcomes. For the EDC side of the same decision, see our comparison of 13 EDC platforms, and for the case for moving off paper diaries, our article on why electronic questionnaires are becoming the rule.

[[faq]]

Sources

• European Medicines Agency (EMA), GCP Inspectors Working Group, Guideline on computerised systems and electronic data in clinical trials (EMA/INS/GCP/112288/2023), 2023.